Lindsey Shapiro is a science writer for Alzheimer's News Today with a PhD in neuroscience. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
The immunotherapy Leqembi, formerly BAN2401, is now FDA-approved for slowing cognitive decline in patients with Alzheimer's disease.| Alzheimer's News Today
Read a summary of the causes Alzheimer's disease, inclouding neurofibrillary tangles, inflammation, vascular and environmental factors, genetics and aging.| Alzheimer's News Today
Marisa Wexler is a senior science writer for Alzheimer's News Today with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Donanemab slowed cognitive, functional ability declines in early Alzheimer’s disease, according to top-line data from a Phase 3 trial.| Alzheimer's News Today
Kisunla (donanemab-azbt) is an antibody-based therapy approved in the U.S. for adults with early symptomatic Alzheimer’s disease.| Alzheimer's News Today
The Alzheimer’s Association celebrates today’s FDA approval of Kisunla™ (donanemab) for the treatment of people living with early symptomatic Alzheimer’s.| Alzheimer's Disease and Dementia
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.| Eli Lilly and Company
Category archive page for News.| Alzheimer's News Today
An advisory committee to the U.S. Food and Drug Administration (FDA) unanimously voted in favor of donanemab for early Alzheimer's.| Alzheimer's News Today
Learn more about Alzheimer's disease, the most common cause of dementia and an irreversible, progressive neurological disorder.| Alzheimer's News Today
